Orforglipron Significantly Lowers HbA1c in Two Additional T2D Trials
Topline data from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes, have been announced.
The ACHIEVE-2 trial (ClinicalTrials.gov Identifier: NCT06192108) compared the efficacy and safety of orforglipron with dapagliflozin in adults with T2D and inadequate glycemic control with metformin.
- Study participants (N=962; baseline hemoglobin A1c [HbA1c] of 8.1%) were randomly assigned to receive orforglipron 3mg, 12mg, or 36mg, or dapagliflozin 10mg once daily.
- The primary endpoint was the change from baseline to week 40 in HbA1c.
Author summary: Orforglipron lowers HbA1c significantly.
More News
- Prediction, pick for Edson Barboza vs. Jalin Turner at UFC 323
- [Kayla Harrison shoots down Ronda Rousey comparison's ahead of her fight with Amanda Nunes]
- Quote of the Day by Warren Buffett: ‘Wall Street is the only place…’
- Kayla Harrison ‘grudge match’ backed to do bigger numbers than Khabib Nurmagomedov vs Conor McGregor
- lookup noun - Definition, usage
- 10 Best Free and Paid Phone Number Lookup Tools
- Kayla Harrison on UFC 324 main event order
- Photoshop CS6 tutorial: Color lookup
- Zen Quotes API | Daily Inspirational Quotes
- Kayla Harrison vs Amanda Nunes Face Off UFC 324